Challenging of ECMO Application in Pediatric Restrictive Cardiomyopathy: Case Report of a Novel Variant

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Jun 10

PMID 38854656

Authors

Yuxi Jin

Juan Xu

Yimin Hua

Haiyang Zhang

Yifei Li

Affiliations

Soon will be listed here.

Abstract

Background: Restrictive cardiomyopathy (RCM) represents a rare cardiovascular disorder stemming from filament-associated genes. Nonetheless, treating RCM presents considerable challenges, particularly concerning device implantation and mechanical support. Furthermore, elucidating the molecular function of specific variants holds promise in benefiting patients and enhancing prognosis, given the significant heterogeneity among RCM variants.

Case Presentation: The proband, an eight-year-old female, was admitted to our hospital post cardiopulmonary resuscitation due to sudden cardiac arrest. Echocardiography revealed bilateral atrial enlargement. Whole-exome sequencing uncovered a novel heterozygous mutation (c.509G>A, p.R170Q) in TNNI3. Evaluation using the MutationTaster application deemed c.509G>A pathogenic (probability = 0.99). Following clinical manifestations, imaging assessments, and genetic screening, the proband received an RCM diagnosis. ECMO was recommended along with continuous renal replacement therapy. However, persistent atrial flutter ensued post-ECMO withdrawal. Attempts to restore cardiac rhythm with cardioversion, metoprolol, and amiodarone proved futile. Subsequent heart failure led to the patient's demise due to cardiac shock. Based on crystal protein structural analysis, we observed that cTnI-R170Q and R170W exerted similar impacts on protein structural stability and formation. However, both differed significantly from cTnI-R170G, primarily influencing amino acid regions 32-79 and 129-149, involved in TnC and actin binding. Therefore, cTnI-R170Q was revealed to induce RCM via the same molecular mechanism as cTnI-R170W.

Conclusion: Managing RCM remains a critical challenge. This study underscores the discouragement of device implantations for cardiac pump functional support in RCM, particularly for non-short-term scheduled HTx. Additionally, considering catheter ablation for atrial fibrosis-induced AFs is recommended. Mechanistically, cTnI-R170Q primarily diminishes troponin-actin interactions and destabilizes thin filaments.

References

Dai H, Wang Q, Su X, Ding Y, Guang X . Pediatric restrictive cardiomyopathy: a case report. J Int Med Res. 2023; 51(8):3000605231188276. PMC: 10469232. DOI: 10.1177/03000605231188276. View

Ji L, Chen J, Qin Y, Yang S . Case report: Rare restrictive cardiomyopathy with ventricular fibrillation as initial symptom rescued by automatic external defibrillator in a pediatric patient. Front Cardiovasc Med. 2022; 9:1058341. PMC: 9691660. DOI: 10.3389/fcvm.2022.1058341. View

Mouton J, Pellizzon A, Goosen A, Kinnear C, Herbst P, Brink P . Diagnostic disparity and identification of two TNNI3 gene mutations, one novel and one arising de novo, in South African patients with restrictive cardiomyopathy and focal ventricular hypertrophy. Cardiovasc J Afr. 2015; 26(2):63-9. PMC: 4815569. DOI: 10.5830/CVJA-2015-019. View

Nunez L, Gimeno-Blanes J, Rodriguez-Garcia M, Monserrat L, Zorio E, Coats C . Somatic MYH7, MYBPC3, TPM1, TNNT2 and TNNI3 mutations in sporadic hypertrophic cardiomyopathy. Circ J. 2013; 77(9):2358-65. DOI: 10.1253/circj.cj-13-0294. View

Chen Y, Yang S, Li J, Wang G, Qin Y, Wang D . Pediatric restrictive cardiomyopathy due to a heterozygous mutation of the TNNI3 gene. J Biomed Res. 2014; 28(1):59-63. PMC: 3904176. DOI: 10.7555/JBR.28.20120105. View

Ploski R, Rydzanicz M, Ksiazczyk T, Franaszczyk M, Pollak A, Kosinska J . Evidence for troponin C (TNNC1) as a gene for autosomal recessive restrictive cardiomyopathy with fatal outcome in infancy. Am J Med Genet A. 2016; 170(12):3241-3248. DOI: 10.1002/ajmg.a.37860. View

Psaras Y, Margara F, Cicconet M, Sparrow A, Repetti G, Schmid M . CalTrack: High-Throughput Automated Calcium Transient Analysis in Cardiomyocytes. Circ Res. 2021; 129(2):326-341. PMC: 8260473. DOI: 10.1161/CIRCRESAHA.121.318868. View

Gomez J, Lorca R, Reguero J, Moris C, Martin M, Tranche S . Screening of the Gene in a Large Cohort of Hypertrophic Cardiomyopathy Patients. Circ Cardiovasc Genet. 2017; 10(2). DOI: 10.1161/CIRCGENETICS.116.001584. View

Zheng M, Huang H, Zhu X, Ho H, Li L, Ji X . Clinical genetic testing in four highly suspected pediatric restrictive cardiomyopathy cases. BMC Cardiovasc Disord. 2022; 22(1):240. PMC: 9131548. DOI: 10.1186/s12872-022-02675-w. View

10.

Zhou N, Weng H, Zhao W, Tang L, Ge Z, Tian F . Gene-echocardiography: refining genotype-phenotype correlations in hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2023; 25(1):127-135. DOI: 10.1093/ehjci/jead200. View

11.

Song X, Wang H, Kashani K, Wang C . Extracorporeal Membrane Oxygenation using a Modified Cardiopulmonary Bypass System. J Transl Int Med. 2022; 10(2):175-177. PMC: 9328033. DOI: 10.2478/jtim-2022-0015. View

12.

Jeong J, Kim Y, Oh S, Lee H, Choi Y, Min K . Identification of concealed cardiomyopathy using next-generation sequencing-based genetic testing in Korean patients initially diagnosed with idiopathic ventricular fibrillation. Europace. 2023; 25(11). PMC: 10639093. DOI: 10.1093/europace/euad313. View

13.

van den Wijngaard A, Volders P, van Tintelen J, Jongbloed J, van den Berg M, Lekanne Deprez R . Recurrent and founder mutations in the Netherlands: cardiac Troponin I (TNNI3) gene mutations as a cause of severe forms of hypertrophic and restrictive cardiomyopathy. Neth Heart J. 2011; 19(7-8):344-51. PMC: 3144325. DOI: 10.1007/s12471-011-0135-z. View

14.

Ishida H, Narita J, Ishii R, Suginobe H, Tsuru H, Wang R . Clinical Outcomes and Genetic Analyses of Restrictive Cardiomyopathy in Children. Circ Genom Precis Med. 2023; 16(4):382-389. DOI: 10.1161/CIRCGEN.122.004054. View

15.

Keyt L, Duran J, Bui Q, Chen C, Miyamoto M, Silva Enciso J . Thin filament cardiomyopathies: A review of genetics, disease mechanisms, and emerging therapeutics. Front Cardiovasc Med. 2022; 9:972301. PMC: 9489950. DOI: 10.3389/fcvm.2022.972301. View

16.

Zangwill S, Naftel D, Lecuyer T, Rosenthal D, Robinson B, Kirklin J . Outcomes of children with restrictive cardiomyopathy listed for heart transplant: a multi-institutional study. J Heart Lung Transplant. 2009; 28(12):1335-40. DOI: 10.1016/j.healun.2009.06.028. View

17.

Janin A, Perouse de Montclos T, Nguyen K, Consolino E, Nadeau G, Rey G . Molecular Diagnosis of Primary Cardiomyopathy in 231 Unrelated Pediatric Cases by Panel-Based Next-Generation Sequencing: A Major Focus on Five Carriers of Biallelic TNNI3 Pathogenic Variants. Mol Diagn Ther. 2022; 26(5):551-560. DOI: 10.1007/s40291-022-00604-3. View

18.

Cimiotti D, Fujita-Becker S, Mohner D, Smolina N, Budde H, Wies A . Infantile restrictive cardiomyopathy: cTnI-R170G/W impair the interplay of sarcomeric proteins and the integrity of thin filaments. PLoS One. 2020; 15(3):e0229227. PMC: 7077804. DOI: 10.1371/journal.pone.0229227. View

19.

Sorrentino U, Gabbiato I, Canciani C, Calosci D, Rigon C, Zuccarello D . Homozygous Mutations and Severe Early Onset Dilated Cardiomyopathy: Patient Report and Review of the Literature. Genes (Basel). 2023; 14(3). PMC: 10048074. DOI: 10.3390/genes14030748. View

20.

Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O . Highly accurate protein structure prediction with AlphaFold. Nature. 2021; 596(7873):583-589. PMC: 8371605. DOI: 10.1038/s41586-021-03819-2. View